Xilio Q3 10-Q: $122.2M Cash to Q1 2028, But Operating Loss Widens to $11.7M
XLO sits 39% above its 52-week low of $6.465.
Summary
Xilio's Q3 10-Q shows a $5.9 million net loss that was helped by a $4.8 million non-cash warrant gain while the operating loss widened to $11.7 million; $122.2 million of cash funds operations into Q1 2028, and 3.4 million Series C warrants expire December 2, 2026 with a strike reset if the stock stays below $10.50.
Key Events · Earnings and Guidance · XLO
-
Q3 Net Loss Flattered by Warrant Gain
Net loss was $5.9 million versus $16.3 million a year earlier, but the improvement came largely from a $4.8 million non-cash gain on warrant remeasurement; the operating loss widened to $11.7 million from $1.9 million.
-
Cash of $122.2M Funds Operations Into Q1 2028
Cash and cash equivalents fell to $122.2 million from $137.5 million at December 31, 2025, with runway guided into the first quarter of 2028.
-
Series C Warrant Reset Looms December 2
3,443,388 Series C warrants at a $10.50 strike expire December 2, 2026; if the closing price is below the strike on December 2, the exercise price resets to the December 1 close and expiry extends to December 31. A full cash exercise would raise up to $36.2 million.
-
New Chief Medical Officer Hired
Yariv Houvras signed an employment agreement dated August 13, 2026 as Chief Medical Officer: $525,000 base salary, 40% target bonus, a 105,000-share option and a $75,000 sign-on bonus.
Analysis · XLO · Life Sciences
The $5.9 million headline net loss is flattered by a $4.8 million non-cash gain on warrant remeasurement; the actual operating loss widened to $11.7 million from $1.9 million a year earlier as R&D rose to $14.8 million. Cash of $122.2 million funds operations into the first quarter of 2028, which removes near-term financing pressure, but the runway assumes no further draws. The real overhang is the 3,443,388 Series C warrants: they expire December 2, 2026, and if the stock is still below the $10.50 strike on December 1 the exercise price resets to that closing price and the expiry extends to December 31 — a full cash exercise would bring in up to $36.2 million, but a reset would reprice that capital raise downward. Also disclosed: a new Chief Medical Officer agreement (Yariv Houvras, $525,000 base, 105,000-share option) and an increase in the 2022 Inducement Plan reserve to 623,555 shares.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XLO was trading at $8.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.2M. The 52-week trading range was $6.47 to $11.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.